Olives J-P, Tounian P, Lamireau T
Gastroenérologie et Nutrition, Département de Pédiatrie, Hôpital des Enfants, 330 av Grande-Bretagne, BP 3119, 31059 Toulouse cedex 9, France.
Arch Pediatr. 2007 Oct;14 Suppl 3:S194-6. doi: 10.1016/s0929-693x(07)80027-3.
The rotavirus is the major cause of infantile gastroenteritis worldwide. In Europe and in industrialized countries, rotavirus infections bring out considerable economic expenses. In France, the burden of health expenses is particularly marked during winter period, the peak of rotavirus infections coinciding with that of the respiratory syncitial virus bronchiolitis, this specificity results in an increase of nosocomial infections during this period and a saturation of beds in paediatric hospitals. Vaccination likely represents the only efficacious adapted response to rotavirus infections. Two vaccines have recently been developed and licensed in France. The development of these two vaccines has followed two different strategies. Despite their differences, these vaccines are both safe and efficient in protecting young infants against severe rotavirus acute gastroenteritis. French Health Authorities decided to postpone rotavirus vaccination for at least two years. According scientific and economic data, the French Speaking Group of Gastroenterology Hepatology and Nutrition disagrees with this decision and states that rotavirus vaccination is universally recommended for healthy infants under six months.
轮状病毒是全球婴幼儿肠胃炎的主要病因。在欧洲及工业化国家,轮状病毒感染带来了相当可观的经济支出。在法国,冬季健康支出负担尤为显著,轮状病毒感染高峰期与呼吸道合胞病毒细支气管炎高峰期重合,这种特殊性导致在此期间医院感染增加,儿科医院床位饱和。疫苗接种可能是应对轮状病毒感染唯一有效的适应性措施。最近有两种疫苗在法国研发并获得许可。这两种疫苗的研发遵循了两种不同策略。尽管存在差异,但这两种疫苗在保护幼儿预防严重轮状病毒急性肠胃炎方面均安全有效。法国卫生当局决定将轮状病毒疫苗接种推迟至少两年。根据科学和经济数据,法语区胃肠病学、肝病学与营养学会不同意这一决定,并指出普遍建议为6个月以下健康婴儿接种轮状病毒疫苗。